Search

Your search keyword '"Patel, Bela"' showing total 627 results
Start Over Author "Patel, Bela"
627 results on '"Patel, Bela"'

1. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.

Author

Park, Han-Sol, Yin, Anna, Barranta, Caelan, Lee, John, Caputo, Christopher, Sachithanandham, Jaiprasath, Li, Maggie, Yoon, Steve, Sitaras, Ioannis, Jedlicka, Anne, Eby, Yolanda, Ram, Malathi, Fernandez, Reinaldo, Baker, Owen, Shenoy, Aarthi, Mosnaim, Giselle, Fukuta, Yuriko, Patel, Bela, Heath, Sonya, Levine, Adam, Meisenberg, Barry, Spivak, Emily, Anjan, Shweta, Huaman, Moises, Blair, Janis, Zand, Martin, Cachay, Edward, Raval, Jay, Kassaye, Seble, Marshall, Christi, Yarava, Anusha, Lane, Karen, McBee, Nichol, Gawad, Amy, Karlen, Nicky, Singh, Atika, Ford, Daniel, Jabs, Douglas, Appel, Lawrence, Shade, David, Lau, Bryan, Ehrhardt, Stephan, Baksh, Sheriza, Shapiro, Janna, Ou, Jiangda, Na, Yu, Knoll, Maria, Ornelas-Gatdula, Elysse, Arroyo-Curras, Netzahualcoyotl, Gniadek, Thomas, Caturegli, Patrizio, Wu, Jinke, Ndahiro, Nelson, Betenbaugh, Michael, Hanley, Daniel, Casadevall, Arturo, Shoham, Shmuel, Bloch, Evan, Gebo, Kelly, Tobian, Aaron, Laeyendecker, Oliver, Pekosz, Andrew, Klein, Sabra, Sullivan, David, Paxton, James, Gerber, Jonathan, Petrini, Joann, Broderick, Patrick, Rausch, William, Cordisco, Marie, Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie, Cruser, Daniel, Oei, Kevin, Abinante, Matthew, Hammitt, Laura, Sutcliffe, Catherine, Currier, Judith, Forthal, Donald, and Ziman, Alyssa

Subjects
COVID-19, Immunoglobulins, Immunotherapy, Humans, COVID-19, COVID-19 Serotherapy, Antibodies, Viral, Immunization, Passive, Hospitalization, SARS-CoV-2, Male, Female, Middle Aged, Adult, Immunoglobulin G, Antibodies, Neutralizing, Double-Blind Method, Aged, Blood Donors, Outpatients
Abstract

BACKGROUNDCOVID-19 convalescent plasma (CCP) virus-specific antibody levels that translate into recipient posttransfusion antibody levels sufficient to prevent disease progression are not defined.METHODSThis secondary analysis correlated donor and recipient antibody levels to hospitalization risk among unvaccinated, seronegative CCP recipients within the outpatient, double-blind, randomized clinical trial that compared CCP to control plasma. The majority of COVID-19 CCP arm hospitalizations (15/17, 88%) occurred in this unvaccinated, seronegative subgroup. A functional cutoff to delineate recipient high versus low posttransfusion antibody levels was established by 2 methods: (i) analyzing virus neutralization-equivalent anti-Spike receptor-binding domain immunoglobulin G (anti-S-RBD IgG) responses in donors or (ii) receiver operating characteristic (ROC) curve analysis.RESULTSSARS-CoV-2 anti-S-RBD IgG antibody was volume diluted 21.3-fold into posttransfusion seronegative recipients from matched donor units. Virus-specific antibody delivered was approximately 1.2 mg. The high-antibody recipients transfused early (symptom onset within 5 days) had no hospitalizations. A CCP-recipient analysis for antibody thresholds correlated to reduced hospitalizations found a statistical significant association between early transfusion and high antibodies versus all other CCP recipients (or control plasma), with antibody cutoffs established by both methods-donor-based virus neutralization cutoffs in posttransfusion recipients (0/85 [0%] versus 15/276 [5.6%]; P = 0.03) or ROC-based cutoff (0/94 [0%] versus 15/267 [5.4%]; P = 0.01).CONCLUSIONIn unvaccinated, seronegative CCP recipients, early transfusion of plasma units in the upper 30% of study donors antibody levels reduced outpatient hospitalizations. High antibody level plasma units, given early, should be reserved for therapeutic use.TRIAL REGISTRATIONClinicalTrials.gov NCT04373460.FUNDINGDepartment of Defense (W911QY2090012); Defense Health Agency; Bloomberg Philanthropies; the State of Maryland; NIH (3R01AI152078-01S1, U24TR001609-S3, 1K23HL151826NIH); the Mental Wellness Foundation; the Moriah Fund; Octapharma; the Healthnetwork Foundation; the Shear Family Foundation; the NorthShore Research Institute; and the Rice Foundation.

Published
2024

2. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial.

Author

Habtehyimer, Feben, Zhu, Xianming, Redd, Andrew, Gebo, Kelly, Abraham, Alison, Patel, Eshan, Laeyendecker, Oliver, Gniadek, Thomas, Fernandez, Reinaldo, Baker, Owen, Ram, Malathi, Currier, Judith, Fukuta, Yuriko, Gerber, Jonathan, Heath, Sonya, Meisenberg, Barry, Huaman, Moises, Levine, Adam, Shenoy, Aarthi, Anjan, Shweta, Blair, Janis, Cruser, Daniel, Hammitt, Laura, Kassaye, Seble, Mosnaim, Giselle, Patel, Bela, Paxton, James, Raval, Jay, Sutcliffe, Catherine, Abinante, Matthew, Oei, Kevin, Cluzet, Valerie, Cordisco, Marie, Greenblatt, Benjamin, Rausch, William, Shade, David, Gawad, Amy, Klein, Sabra, Pekosz, Andrew, Shoham, Shmuel, Casadevall, Arturo, Bloch, Evan, Hanley, Daniel, Tobian, Aaron, Sullivan, David, Forthal, Donald, and Cachay, Edward

Subjects
COVID-19, COVID-19 serotherapy, SARS-CoV-2, chemokines, convalescent plasma, cytokines, randomized trial, Humans, COVID-19, COVID-19 Serotherapy, Interleukin-6, SARS-CoV-2, Cytokines, Immunization, Passive
Abstract

This study examined the role that cytokines may have played in the beneficial outcomes found when outpatient individuals infected with SARS-CoV-2 were transfused with COVID-19 convalescent plasma (CCP) early in their infection. We found that the pro-inflammatory cytokine IL-6 decreased significantly faster in patients treated early with CCP. Participants with COVID-19 treated with CCP later in the infection did not have the same effect. This decrease in IL-6 levels after early CCP treatment suggests a possible role of inflammation in COVID-19 progression. The evidence of IL-6 involvement brings insight into the possible mechanisms involved in CCP treatment mitigating SARS-CoV-2 severity.

Published
2024

3. Early antibody treatment, inflammation, and risk of post-COVID conditions.

Author

Gebo, Kelly, Heath, Sonya, Fukuta, Yuriko, Zhu, Xianming, Baksh, Sheriza, Abraham, Allison, Habtehyimer, Feben, Shade, David, Ruff, Jessica, Ram, Malathi, Laeyendecker, Oliver, Fernandez, Reinaldo, Patel, Eshan, Baker, Owen, Shoham, Shmuel, Cachay, Edward, Currier, Judith, Gerber, Jonathan, Meisenberg, Barry, Hammitt, Laura, Huaman, Moises, Levine, Adam, Mosnaim, Giselle, Patel, Bela, Paxton, James, Raval, Jay, Sutcliffe, Catherine, Anjan, Shweta, Gniadek, Thomas, Kassaye, Seble, Blair, Janis, Lane, Karen, McBee, Nichol, Gawad, Amy, Das, Piyali, Klein, Sabra, Pekosz, Andrew, Bloch, Evan, Hanley, Daniel, Casadevall, Arturo, Tobian, Aaron, Sullivan, David, and Forthal, Donald

Subjects
COVID-19, COVID-19 serotherapy, chemokines, cytokines, interleukin-6, post-COVID condition (PCC), post-acute sequelae of COVID (PASC)
Abstract

Post-COVID conditions (PCCs) are common and have significant morbidity. Risk factors for PCC include advancing age, female sex, obesity, and diabetes mellitus. Little is known about treatment, inflammation, and PCC. Among 882 individuals with confirmed SARS-CoV-2 infection participating in a randomized trial of COVID-19 convalescent plasma (CCP) vs control plasma with available biospecimens and symptom data, the association between early CCP treatment, cytokine levels, and PCC was evaluated. Cytokine and chemokine levels were assessed at baseline, day 14, and day 90 using a multiplexed sandwich immunoassay (Meso Scale Discovery). Presence of any self-reported PCC symptoms was assessed at day 90. Associations between CCP treatment, cytokine levels, and PCC were examined using multivariate logistic regression models. One third of the 882 participants had day 90 PCC symptoms, with fatigue (14.5%) and anosmia (14.5%) being most common. Cytokine levels decreased from baseline to day 90. In a multivariable analysis, female sex (adjusted odds ratio [AOR] = 2.69 [1.93-3.81]), older age (AOR = 1.32 [1.17-1.50]), and elevated baseline levels of IL-6 (AOR = 1.59 [1.02-2.47]) were independently associated with development of PCC. Those who received early CCP treatment (≤5 days after symptom onset) compared to late CCP treatment had statistically significant lower odds of PCC. IMPORTANCE Approximately 20% of individuals infected with SARS-CoV-2 experienced long-term health effects, as defined PCC. However, it is unknown if there are any early biomarkers associated with PCC or whether early intervention treatments may decrease the risk of PCC. In a secondary analysis of a randomized clinical trial, this study demonstrates that among outpatients with SARS-CoV-2, increased IL-6 at time of infection is associated with increased odds of PCC. In addition, among individuals treated early, within 5 days of symptom onset, with COVID-19 convalescent plasma, there was a trend for decreased odds of PCC after adjusting for other demographic and clinical characteristics. Future treatment studies should be considered to evaluate the effect of early treatment and anti-IL-6 therapies on PCC development.

Published
2023

4. Transfusion reactions associated with COVID-19 convalescent plasma in outpatient clinical trials.

Author

Huaman, Moises, Raval, Jay, Paxton, James, Mosnaim, Giselle, Patel, Bela, Anjan, Shweta, Meisenberg, Barry, Levine, Adam, Marshall, Christi, Yarava, Anusha, Shenoy, Aarthi, Heath, Sonya, Currier, Judith, Fukuta, Yuriko, Blair, Janis, Spivak, Emily, Petrini, Joann, Broderick, Patrick, Rausch, William, Cordisco, MarieElena, Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie, Cruser, Daniel, Oei, Kevin, Abinante, Matthew, Hammitt, Laura, Sutcliffe, Catherine, Forthal, Donald, Zand, Martin, Cachay, Edward, Kassaye, Seble, Ram, Malathi, Wang, Ying, Das, Piyali, Lane, Karen, McBee, Nichol, Gawad, Amy, Karlen, Nicky, Ford, Daniel, Laeyendecker, Oliver, Pekosz, Andrew, Klein, Sabra, Ehrhardt, Stephan, Lau, Bryan, Baksh, Sheriza, Shade, David, Casadevall, Arturo, Hanley, Daniel, Ou, Jiangda, Gniadek, Thomas, Ziman, Alyssa, Shoham, Shmuel, Gebo, Kelly, Bloch, Evan, Tobian, Aaron, Sullivan, David, and Gerber, Jonathan

Subjects
Humans, COVID-19, COVID-19 Serotherapy, Immunization, Passive, Outpatients, SARS-CoV-2, Transfusion Reaction, Urticaria, Randomized Controlled Trials as Topic
Abstract

BACKGROUND: COVID-19 convalescent plasma (CCP) is an important therapeutic option for outpatients at high risk of hospitalization from SARS-CoV-2 infection. We assessed the safety of outpatient CCP transfusions administered during clinical trials. STUDY DESIGN AND METHODS: We analyzed data pertaining to transfusion-related reactions from two randomized controlled trials in the U.S. that evaluated the efficacy of CCP versus control plasma in various ambulatory settings. Multivariable logistic regression was used to assess whether CCP was associated with transfusion reactions, after adjusting for potential confounders. RESULTS: The combined study reported 79/1351 (5.9%) adverse events during the transfusion visit, with the majority 62/1351 (4.6%) characterized by mild, allergic-type findings of urticaria, and/or pruritus consistent with minor allergic transfusion reactions; the other reported events were attributed to the patients underlying disease, COVID-19, or vasovagal in nature. We found no difference in the likelihood of allergic transfusion reactions between those receiving CCP versus control plasma (adjusted odds ratio [AOR], 0.75; 95% CI, 0.43-1.31). Risk of urticaria and/or pruritus increased with a pre-existing diagnosis of asthma (AOR, 2.33; 95% CI, 1.16-4.67). We did not observe any CCP-attributed antibody disease enhancement in participants with COVID-19 or increased risk of infection. There were no life-threatening severe transfusion reactions and no patients required hospitalization related to transfusion-associated complications. DISCUSSION: Outpatient plasma administration was safely performed for nearly 1400 participants. CCP is a safe therapeutic option for outpatients at risk of hospitalization from COVID-19.

Published
2023

5. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study.

Author

Hammitt, Laura, Kassaye, Seble, Mosnaim, Giselle, Patel, Bela, Paxton, James, Raval, Jay, Sutcliffe, Catherine, Abinante, Matthew, Broderick, Patrick, Cluzet, Valerie, Cordisco, Marie, Greenblatt, Benjamin, Petrini, Joann, Rausch, William, Shade, David, Lane, Karen, Gawad, Amy, Klein, Sabra, Pekosz, Andrew, Shoham, Shmuel, Casadevall, Arturo, Bloch, Evan, Hanley, Daniel, Sullivan, David, Tobian, Aaron, Zhu, Xianming, Gebo, Kelly, Abraham, Alison, Habtehyimer, Feben, Patel, Eshan, Laeyendecker, Oliver, Gniadek, Thomas, Fernandez, Reinaldo, Baker, Owen, Ram, Malathi, Cachay, Edward, Currier, Judith, Fukuta, Yuriko, Gerber, Jonathan, Heath, Sonya, Meisenberg, Barry, Huaman, Moises, Levine, Adam, Shenoy, Aarthi, Anjan, Shweta, Blair, Janis, Cruser, Daniel, and Forthal, Donald

Subjects
United States, Humans, Female, Male, Adolescent, Adult, COVID-19, Vascular Endothelial Growth Factor A, SARS-CoV-2, COVID-19 Vaccines, Interleukin-7, Interleukin-8, Prospective Studies, COVID-19 Serotherapy, Cytokines
Abstract

BACKGROUND: Cytokines and chemokines play a critical role in the response to infection and vaccination. We aimed to assess the longitudinal association of COVID-19 vaccination with cytokine and chemokine concentrations and trajectories among people with SARS-CoV-2 infection. METHODS: In this longitudinal, prospective cohort study, blood samples were used from participants enrolled in a multi-centre randomised trial assessing the efficacy of convalescent plasma therapy for ambulatory COVID-19. The trial was conducted in 23 outpatient sites in the USA. In this study, participants (aged ≥18 years) were restricted to those with COVID-19 before vaccination or with breakthrough infections who had blood samples and symptom data collected at screening (pre-transfusion), day 14, and day 90 visits. Associations between COVID-19 vaccination status and concentrations of 21 cytokines and chemokines (measured using multiplexed sandwich immunoassays) were examined using multivariate linear mixed-effects regression models, adjusted for age, sex, BMI, hypertension, diabetes, trial group, and COVID-19 waves (pre-alpha or alpha and delta). FINDINGS: Between June 29, 2020, and Sept 30, 2021, 882 participants recently infected with SARS-CoV-2 were enrolled, of whom 506 (57%) were female and 376 (43%) were male. 688 (78%) of 882 participants were unvaccinated, 55 (6%) were partly vaccinated, and 139 (16%) were fully vaccinated at baseline. After adjusting for confounders, geometric mean concentrations of interleukin (IL)-2RA, IL-7, IL-8, IL-15, IL-29 (interferon-λ), inducible protein-10, monocyte chemoattractant protein-1, and tumour necrosis factor-α were significantly lower among the fully vaccinated group than in the unvaccinated group at screening. On day 90, fully vaccinated participants had approximately 20% lower geometric mean concentrations of IL-7, IL-8, and vascular endothelial growth factor-A than unvaccinated participants. Cytokine and chemokine concentrations decreased over time in the fully and partly vaccinated groups and unvaccinated group. Log10 cytokine and chemokine concentrations decreased faster among participants in the unvaccinated group than in other groups, but their geometric mean concentrations were generally higher than fully vaccinated participants at 90 days. Days since full vaccination and type of vaccine received were not correlated with cytokine and chemokine concentrations. INTERPRETATION: Initially and during recovery from symptomatic COVID-19, fully vaccinated participants had lower concentrations of inflammatory markers than unvaccinated participants suggesting vaccination is associated with short-term and long-term reduction in inflammation, which could in part explain the reduced disease severity and mortality in vaccinated individuals. FUNDING: US Department of Defense, National Institutes of Health, Bloomberg Philanthropies, State of Maryland, Mental Wellness Foundation, Moriah Fund, Octapharma, HealthNetwork Foundation, and the Shear Family Foundation.

Published
2023

7. Symptom Duration and Resolution With Early Outpatient Treatment of Convalescent Plasma for Coronavirus Disease 2019: A Randomized Trial

Author

Baksh, Sheriza N, Heath, Sonya L, Fukuta, Yuriko, Shade, David, Meisenberg, Barry, Bloch, Evan M, Tobian, Aaron AR, Spivak, Emily S, Patel, Bela, Gerber, Jonathan, Raval, Jay S, Forthal, Donald, Paxton, James, Mosnaim, Giselle, Anjan, Shweta, Blair, Janis, Cachay, Edward, Currier, Judith, Das, Piyali, Huaman, Moises, Sutcliffe, Catherine, Yarava, Anusha, Casadevall, Arturo, Sullivan, David, Hanley, Daniel, and Gebo, Kelly A

Subjects
Clinical Research, Clinical Trials and Supportive Activities, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Humans, COVID-19, SARS-CoV-2, Outpatients, Syndrome, Immunization, Passive, COVID-19 Serotherapy, COVID-19 serotherapy, plasma, symptom duration, Biological Sciences, Medical and Health Sciences, Microbiology
Abstract

BackgroundCoronavirus disease 2019 (COVID-19) convalescent plasma (CCP) reduces hospitalizations among outpatients treated early after symptom onset. It is unknown whether CCP reduces time to symptom resolution among outpatients.MethodsWe evaluated symptom resolution at day 14 by trial arm using an adjusted subdistribution hazard model, with hospitalization as a competing risk. We also assessed the prevalence of symptom clusters at day 14 between treatments. Clusters were defined based on biologic clustering, impact on ability to work, and an algorithm.ResultsAmong 1070 outpatients followed up after transfusion, 381 of 538 (70.8%) receiving CCP and 381 of 532 (71.6%) receiving control plasma were still symptomatic (P = .78) at day 14. Associations between CCP and symptom resolution by day 14 did not differ significantly from those in controls after adjustment for baseline characteristics (adjusted subdistribution hazard ratio, 0.99; P = .62). The most common cluster consisted of cough, fatigue, shortness of breath, and headache and was found in 308 (57.2%) and 325 (61.1%) of CCP and control plasma recipients, respectively (P = .16).ConclusionsIn this trial of outpatients with early COVID-19, CCP was not associated with faster resolution of symptoms compared with control. Overall, there were no differences by treatment in the prevalence of each symptom or symptom clusters at day 14.Clinical trials registrationNCT04373460.

Published
2023

9. Transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection: a double-blinded, phase 2 randomized, controlled trial

Author

Shoham, Shmuel, Bloch, Evan M, Casadevall, Arturo, Hanley, Daniel, Lau, Bryan, Gebo, Kelly, Cachay, Edward, Kassaye, Seble G, Paxton, James H, Gerber, Jonathan, Levine, Adam C, Naeim, Arash, Currier, Judith, Patel, Bela, Allen, Elizabeth S, Anjan, Shweta, Appel, Lawrence, Baksh, Sheriza, Blair, Paul W, Bowen, Anthony, Broderick, Patrick, Caputo, Christopher A, Cluzet, Valerie, Cordisco, Marie Elena, Cruser, Daniel, Ehrhardt, Stephan, Forthal, Donald, Fukuta, Yuriko, Gawad, Amy L, Gniadek, Thomas, Hammel, Jean, Huaman, Moises A, Jabs, Douglas A, Jedlicka, Anne, Karlen, Nicky, Klein, Sabra, Laeyendecker, Oliver, Lane, Karen, McBee, Nichol, Meisenberg, Barry, Merlo, Christian, Mosnaim, Giselle, Park, Han-Sol, Pekosz, Andrew, Petrini, Joann, Rausch, William, Shade, David M, Shapiro, Janna R, Singleton, J Robinson, Sutcliffe, Catherine, Thomas, David L, Yarava, Anusha, Zand, Martin, Zenilman, Jonathan M, Tobian, Aaron AR, and Sullivan, David J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Biodefense, Lung, Pneumonia, Clinical Trials and Supportive Activities, Vaccine Related, Prevention, Infectious Diseases, Emerging Infectious Diseases, Clinical Research, Infection, Good Health and Well Being, Humans, Adolescent, Adult, SARS-CoV-2, COVID-19, Post-Exposure Prophylaxis, COVID-19 Serotherapy, Double-Blind Method, Immunization, Passive, post-exposure-prophylaxis, convalescent plasma, transfusion, Biological Sciences, Medical and Health Sciences, Microbiology, Clinical sciences
Abstract

BackgroundThe efficacy of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. CCP might prevent infection when administered before symptoms or laboratory evidence of infection.MethodsThis double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320 by Euroimmun ELISA) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed coronavirus disease 2019 (COVID-19) in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was new SARS-CoV-2 infection.ResultsIn total, 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 transfused at 19 sites across the United States from June 2020 to March 2021. Two were excluded for screening SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) positivity. Of the remaining 168 participants, 12/81 (14.8%) CCP and 13/87 (14.9%) control recipients developed SARS-CoV-2 infection; 6 (7.4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. Efficacy by restricted mean infection free time (RMIFT) by 28 days for all SARS-CoV-2 infections (25.3 vs 25.2 days; P = .49) and COVID-19 (26.3 vs 25.9 days; P = .35) was similar for both groups.ConclusionsAdministration of high-titer CCP as post-exposure prophylaxis, although appearing safe, did not prevent SARS-CoV-2 infection.Clinical trials registrationNCT04323800.

Published
2023

10. Phosphoproteomics predict response to midostaurin plus chemotherapy in independent cohorts of FLT3-mutated acute myeloid leukaemia

Author

Borek, Weronika E., Nobre, Luis, Pedicona, S. Federico, Campbell, Amy E., Christopher, Josie A., Nawaz, Nazrath, Perkins, David N., Moreno-Cardoso, Pedro, Kelsall, Janet, Ferguson, Harriet R., Patel, Bela, Gallipoli, Paolo, Arruda, Andrea, Ambinder, Alex J., Thompson, Andrew, Williamson, Andrew, Ghiaur, Gabriel, Minden, Mark D., Gribben, John G., Britton, David J., Cutillas, Pedro R., and Dokal, Arran D.

Published
2024
Full Text
View/download PDF

11. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

Author

Sahner, David, Tierney, John, Vogel, Susan E., Herpin, Betsey R., Smolskis, Mary C., McKay, Laura A., Cahill, Kelly, Crew, Page, Sardana, Ratna, Raim, Sharon Segal, Hensely, Lisa, Lorenzo, Johsua, Mock, Rebecca, Zuckerman, Judith, Atri, Negin, Miller, Mark, Vallee, David, Chung, Lucy, Kang, Nayon, Barrett, Kevin, Adam, Stacey J., Read, Sarah, Draghia-Akli, Ruxandra, Currier, Judy, Hughes, Eric, Harrigan, Rachel H., Amos, Laura, Carlsen, Amy, Carter, Anita, Collins, Gary, Davis, Bionca, Denning, Eileen, DuChene, Alain, Eckroth, Kate, Engen, Nicole, Frase, Alex, Gandits, Greg, Grund, Birgit, Harrison, Merrie, Hurlbut, Nancy, Kaiser, Payton, Koopmeiners, Joseph, Larson, Gregg, Meger, Sue, Mistry, Shweta Sharma, Murray, Thomas, Nelson, Ray, Quan, Kien, Quan, Siu Fun, Reilly, Cavan, Siegel, Lianne, Thompson, Greg, Vock, David, Walski, Jamie, Gelijns, Annetine C., Moskowitz, Alan J., Bagiella, Emilia, Moquete, Ellen, O'Sullivan, Karen, Marks, Mary E., Accardi, Evan, Kinzel, Emily, Burris, Sarah, Bedoya, Gabriela, Gupta, Lola, Overbey, Jessica R., Santos, Milerva, Gillinov, Marc A., Miller, Marissa A., Taddei-Peters, Wendy C., Fenton, Kathleen, Sandkovsky, Uriel, Gottlieb, Robert L., Mack, Michael, Berhe, Mezgebe, Haley, Clinton, Dishner, Emma, Bettacchi, Christopher, Golden, Kevin, Duhaime, Erin, Ryan, Madison, Tallmadge, Catherine, Estrada, Lorie, Jones, Felecia, Villa, Samatha, Wang, Samatha, Robert, Raven, Coleman, Tanquinisha, Clariday, Laura, Baker, Rebecca, Hurutado-Rodriguez, Mariana, Iram, Nazia, Fresnedo, Michelle, Davis, Allyson, Leonard, Kiara, Ramierez, Noelia, Thammavong, Jon, Duque, Krizia, Turner, Emma, Fisher, Tammy, Robinson, Dianna, Ransom, Desirae, Maldonado, Nicholas, Lusk, Erica, Killian, Aaron, Palacious, Adriana, Solis, Edilia, Jerrow, Janet, Watts, Matthew, Whitacre, Heather, Cothran, Elizabeth, Smith, Peter K., Barkauskas, Christina E., Vekstein, Andrew M., Ko, Emily R., Dreyer, Grace R., Stafford, Neil, Brooks, Megan, Der, Tatyana, Witte, Marie, Gamarallage, Ruwan, Franzone, John, Ivey, Noel, Lumsden, Rebecca H., Mosaly, Nilima, Mourad, Ahmaad, Holland, Thomas L., Motta, Mary, Lane, Kathleen, McGowan, Lauren M., Stout, Jennifer, Aloor, Heather, Bragg, Kennesha M., Toledo, Barvina, McLendon-Arvik, Beth, Bussadori, Barbara, Hollister, Beth A., Griffin, Michelle, Giangiacomo, Dana M., Rodriguez, Vicente, Bokhart, Gordon, Eichman, Sharon M., Parrino, Patrick E., Spindel, Stephen, Bansal, Aditya, Baumgarten, Katherine, Hand, Johnathan, Vonderhaar, Derek, Nossaman, Bobby, Sylvia Laudun, Ames, DeAnna, Broussard, Shane, Hernandez, Nilmo, Isaac, Geralyn, Dinh, Huan, Zheng, Yiling, Tran, Sonny, McDaniel, Hunter, Crovetto, Nicolle, Perin, Emerson, Costello, Briana, Manian, Prasad, Sohail, M. Rizwan, Postalian, Alexander, Hinsu, Punit, Watson, Carolyn, Chen, James, Fink, Melyssa, Sturgis, Lydia, Walker, Kim, Mahon, Kim, Parenti, Jennifer, Kappenman, Casey, Knight, Aryn, Sturek, Jeffrey M., Barros, Andrew, Enfield, Kyle B., Kadl, Alexandra, Green, China J., Simon, Rachel M., Fox, Ashley, Thornton, Kara, Adams, Amy, Badhwar, Vinay, Sharma, Sunil, Peppers, Briana, McCarthy, Paul, Krupica, Troy, Sarwari, Arif, Reece, Rebecca, Fornaresico, Lisa, Glaze, Chad, Evans, Raquel, Di, Fang, Carlson, Shawn, Aucremanne, Tanja, Tennant, Connie, Sutton, Lisa Giblin, Buterbaugh, Sabrina, Williams, Roger, Bunner, Robin, Traverse, Jay H., Rhame, Frank, Huelster, Joshua, Kethireddy, Rajesh, Davies, Irena, Salamanca, Julianne, Majeski, Christine, Skelton, Paige, Zarambo, Maria, Sarafolean, Andrea, Bowdish, Michael E., Borok, Zea, Wald-Dickler, Noah, Hutcheon, Douglass, Towfighi, Amytis, Lee, Mary, Lewis, Meghan R., Spellberg, Brad, Sher, Linda, Sharma, Aniket, Olds, Anna P., Justino, Chris, Loxano, Edward, Romero, Chris, Leong, Janet, Rodina, Valentina, Quesada, Christine, Hamilton, Luke, Escobar, Jose, Leshnower, Brad, Bender, William, Sharifpour, Milad, Miller, Jeffrey, Farrington, Woodrow, Baio, Kim T., McBride, Mary, Fielding, Michele, Mathewson, Sonya, Porte, Kristina, Maton, Missy, Ponder, Chari, Haley, Elisabeth, Spainhour, Christine, Rogers, Susan, Tyler, Derrick, Madathil, Ronson J., Rabin, Joseph, Levine, Andrea, Saharia, Kapil, Tabatabai, Ali, Lau, Christine, Gammie, James S., Peguero, Maya-Loren, McKernan, Kimberly, Audette, Mathew, Fleischmann, Emily, Akbari, Kreshta, Lee, Myounghee, Chi, Andrew, Salehi, Hanna, Pariser, Alan, Nyguyen, Phuong Tran, Moore, Jessica, Gee, Adrienne, Vincent, Shelika, Zuckerman, Richard A., Iribarne, Alexander, Metzler, Sara, Shipman, Samantha, Johnson, Haley, Newton, Crystallee, Parr, Doug, Miller, Leslie, Schelle, Beth, McLean, Sherry, Rothbaum, Howard R., Alvarez, Michael S., Kalan, Shivam P., Germann, Heather H., Hendershot, Jennifer, Moroney, Karen, Herring, Karen, Cook, Sharri, Paul, Pam, Walker-Ignasiak, Rebecca, North, Crystal, Oldmixon, Cathryn, Ringwood, Nancy, Muzikansky, Ariela, Morse, Richard, Fitzgerald, Laura, Morin, Haley D., Brower, Roy G., Reineck, Lora A., Bienstock, Karen, Steingrub, Jay H., Hou, Peter K., Steingrub, Jay S., Tidswell, Mark A., Kozikowski, Lori-Ann, Kardos, Cynthia, DeSouza, Leslie, Romain, Sarah, Thornton-Thompson, Sherell, Talmor, Daniel, Shapiro, Nathan, Andromidas, Konstantinos, Banner-Goodspeed, Valerie, Bolstad, Michael, Boyle, Katherine L., Cabrera, Payton, deVilla, Arnaldo, Ellis, Joshua C., Grafals, Ana, Hayes, Sharon, Higgins, Conor, Kurt, Lisa, Kurtzman, Nicholas, Redman, Kimberly, Rosseto, Elinita, Scaffidi, Douglas, Filbin, Michael R., Hibbert, Kathryn A., Parry, Blair, Margolin, Justin, Hillis, Brooklynn, Hamer, Rhonda, Brait, Kelsey, Beakes, Caroline, McKaig, Brenna, Kugener, Eleonore, Jones, Alan E., Galbraith, James, Nandi, Utsav, Peacock, Rebekah, Hendey, Gregory, Kangelaris, Kirsten, Ashktorab, Kimia, Gropper, Rachel, Agrawal, Anika, Yee, Kimberley J., Jauregui, Alejandra E., Zhuo, Hanjing, Almasri, Eyad, Fayed, Mohamed, Hubel, Kinsley A., Hughes, Alyssa R., Garcia, Rebekah L., Lim, George W., Chang, Steven Y., Lin, Michael Y., Vargas, Julia, Sihota, Hena, Beutler, Rebecca, Agarwal, Trisha, Wilson, Jennifer G., Vojnik, Rosemary, Perez, Cynthia, McDowell, Jordan H., Roque, Jonasel, Wang, Henry, Huebinger, Ryan M., Patel, Bela, Vidales, Elizabeth, Albertson, Timothy, Hardy, Erin, Harper, Richart, Moss, Marc A., Baduashvili, Amiran, Chauhan, Lakshmi, Douin, David J., Martinez, Flora, Finck, Lani L., Bastman, Jill, Howell, Michelle, Higgins, Carrie, McKeehan, Jeffrey, Finigan, Jay, Stubenrauch, Peter, Janssen, William J., Griesmer, Christine, VerBurg, Olivia, Hyzy, Robert C., Park, Pauline K., Nelson, Kristine, McSparron, Jake I., Co, Ivan N., Wang, Bonnie R., Jimenez, Jose, Olbrich, Norman, McDonough, Kelli, Jia, Shijing, Hanna, Sinan, Gong, Michelle N., Richardson, Lynne D., Nair, Rahul, Lopez, Brenda, Amosu, Omowunmi, Offor, Obiageli, Tzehaie, Hiwet, Nkemdirim, William, Boujid, Sabah, Mosier, Jarrod M., Hypes, Cameron, Campbell, Elizabeth Salvagio, Bixby, Billie, Gilson, Boris, Lopez, Anitza, Bime, Christian, Parthasarathy, Sairam, Cano, Ariana M., Hite, R. Duncan, Terndrup, Thomas E., Wiedemann, Herbert P., Hudock, Kristin, Tanzeem, Hammad, More, Harshada, Martinkovic, Jamie, Sellers, Susan, Houston, Judy, Burns, Mary, Kiran, Simra, Roads, Tammy, Kennedy, Sarah, Duggal, Abhijit, Thiruchelvam, Nirosshan, Ashok, Kiran, King, Alexander H., Mehkri, Omar, Dugar, Siddharth, Sahoo, Debasis, Yealy, Donald M., Angus, Derek C., Weissman, Alexandra J., Vita, Tina M., Berryman, Emily, Hough, Catherine L., Khan, Akram, Krol, Olivia F., Mills, Emmanuel, Kinjal, Mistry, Briceno, Genesis, Reddy, Raju, Hubel, Kinsley, Jouzestani, Milad K., McDougal, Madeline, Deshmukh, Rupali, Johnston, Nicholas J., Robinson, Bryce H., Gundel, Staphanie J., Katsandres, Sarah C., Chen, Peter, Torbati, Sam S., Parimon, Tanyalak, Caudill, Antonina, Mattison, Brittany, Jackman, Susan E., Chen, Po-En, Bayoumi, Emad, Ojukwu, Cristabelle, Fine, Devin, Weissberg, Gwendolyn, Isip, Katherine, Choi-Kuaea, Yunhee, Mehdikhani, Shaunt, Dar, Tahir B., Fleury Augustin, Nsole Biteghe, Tran, Dana, Dukov, Jennifer Emilow, Matusov, Yuri, Choe, June, Hindoyan, Niree A., Wynter, Timothy, Pascual, Ethan, Clapham, Gregg J., Herrera, Lisa, Caudill, Antonia, O’Mahony, D. Shane, Nyatsatsang, Sonam T., Wilson, David M., Wallick, Julie A., Duven, Alexandria M., Fletcher, Dakota D., Miller, Chadwick, Files, D. Clark, Gibbs, Kevin W., Flores, Lori S., LaRose, Mary E., Landreth, Leigha D., Palacios, D. Rafael, Parks, Lisa, Hicks, Madeline, Goodwin, Andrew J., Kilb, Edward F., Lematty, Caitlan T., Patti, Kerilyn, Grady, Abigail, Rasberry, April, Morris, Peter E., Sturgill, Jamie L., Cassity, Evan P., Dhar, Sanjay, Montgomery-Yates, Ashley A., Pasha, Sarah N., Mayer, Kirby P., Pharm.D., Brittany Bissel, Trott, Terren, Rehman, Shahnaz, de Wit, Marjolein, Mason, Jessica, Bledsoe, Joseph, Knowlton, Kirk U., Brown, Samuel, Lanspa, Michael, Leither, Lindsey, Pelton, Ithan, Armbruster, Brent P., Montgomery, Quinn, Kumar, Naresh, Fergus, Melissa, Imel, Karah, Palmer, Ghazal, Webb, Brandon, Klippel, Carolyn, Jensen, Hannah, Duckworth, Sarah, Gray, Andrew, Burke, Tyler, Knox, Dan, Lumpkin, Jenna, Aston, Valerie T., Applegate, Darrin, Serezlic, Erna, Brown, Katie, Merril, Mardee, Harris, Estelle S., Middleton, Elizabeth A., Barrios, Macy A.G., Greer, Jorden, Schmidt, Amber D., Webb, Melissa K., Paine, Roert, Callahan, Sean J., Waddoups, Lindsey J., Yamane, Misty B., Self, Wesley H., Rice, Todd W., Casey, Jonathan D., Johnson, Jakea, Gray, Christopher, Hays, Margaret, Roth, Megan, Menon, Vidya, Kasubhai, Moiz, Pillai, Anjana, Daniel, Jean, Sittler, Daniel, Kanna, Balavenkatesh, Jilani, Nargis, Amaro, Francisco, Santana, Jessica, Lyakovestsky, Aleksandr, Madhoun, Issa, Desroches, Louis Marie, Amadon, Nicole, Bahr, Alaa, Ezzat, Imaan, Guerrero, Maryanne, Padilla, Joane, Fullmer, Jessie, Singh, Inderpreet, Ali Shah, Syed Hamad, Narang, Rajeev, Mock, Polly, Shadle, Melissa, Hernandez, Brenda, Welch, Kevin, Payne, Andrea, Ertl, Gabriela, Canario, Daniel, Barrientos, Isabel, Goss, Danielle, DeVries, Mattie, Folowosele, Ibidolapo, Garner, Dorothy, Gomez, Mariana, Price, Justin, Bansal, Ekta, Wong, Jim, Faulhaber, Jason, Fazili, Tasaduq, Yeary, Brian, Ndolo, Ruth, Bryant, Christina, Smigeil, Bridgette, Robinson, Philip, Najjar, Rana, Jones, Patrice, Nguyen, Julie, Chin, Christina, Taha, Hassan, Najm, Salah, Smith, Christopher, Moore, Jason, Nassar, Talal, Gallinger, Nick, Christian, Amy, Mauer, D’Amber, Phipps, Ashley, Waters, Michael, Zepeda, Karla, Coslet, Jordan, Landazuri, Rosalynn, Pineda, Jacob, Uribe, Nicole, Garcia, Jose Ruiz, Barbabosa, Cecilia, Sandler, Kaitlyn, Overcash, J. Scott, Marquez, Adrienna, Chu, Hanh, Lee, Kia, Quillin, Kimberly, Garcia, Andrea, Lew, Pauline, Rogers, Ralph, Shehadeh, Fadi, Mylona, Evangelia K., Kaczynski, Matthew, Tran, Quynh-Lam, Benitez, Gregorio, Mishra, Biswajit, Felix, Lewis Oscar, Vafea, Maria Tsikala, Atalla, Eleftheria, Davies, Robin, Hedili, Salma, Monkeberg, Maria Andrea, Tabler, Sandra, Harrington, Britt, Meegada, Sreenath, Koripalli, Venkata Sandeep, Muddana, Prithvi, Jain, Lakshay, Undavalli, Chaitanya, Kavya, Parasa, Ibiwoye, Mofoluwaso, Akilo, Hameed, Lovette, Bryce D., Wylie, Jamie-Crystal, Smith, Diana M., Poon, Kenneth, Eckardt, Paula, Heysu, Rubio-Gomez, Sundararaman, Nithya, Alaby, Doris, Sareli, Candice, Sánchez, Adriana, Popielski, Laura, Kambo, Amy, Viens, Kimberley, Turner, Melissa, Vjecha, Michael J., Weintrob, Amy, Brar, Indira, Markowitz, Norman, Pastor, Erika, Corpuz, Roweena, Alangaden, George, McKinnon, John, Ramesh, Mayur, Herc, Erica, Yared, Nicholas, Lanfranco, Odaliz Abreu, Rivers, Emanuel, Swiderek, Jennifer, Gupta, Ariella Hodari, Pabla, Pardeep, Eliya, Sonia, Jazrawi, Jehan, Delor, Jeremy, Desai, Mona, Cook, Aaron, Jaehne, Anja Kathrina, Gill, Jasreen Kaur, Renaud, Sheri, Sarveswaran, Siva, Gardner, Edward, Scott, James, Bianchini, Monica, Melvin, Casey, Kim, Gina, Wyles, David, Kamis, Kevin, Miller, Rachel, Douglas, Ivor, Haukoos, Jason, Hicks, Carrie, Lazarte, Susana, Marines-Price, Rubria, Osuji, Alice, Agbor Agbor, Barbine Tchamba, Petersen, Tianna, Kamel, Dena, Hansen, Laura, Garcia, Angie, Cha, Christine, Mozaffari, Azadeh, Hernandez, Rosa, Cutrell, James, Kim, Mina, DellaValle, Natalie, Gonzales, Sonia, Somboonwit, Charurut, Oxner, Asa, Guerra, Lucy, Hayes, Michael, Nguyen, Thi, Tran, Thanh, Pinto, Avenette, Hatlen, Timothy, Anderson, Betty, Zepeda-Gutierrez, Ana, Martin, Dannae, Temblador, Cindi, Cuenca, Avon, Tanoviceanu, Roxanne, Prieto, Martha, Guerrero, Mario, Daar, Eric, Correa, Ramiro, Hartnell, Gabe, Wortmann, Glenn, Doshi, Saumil, Moriarty, Theresa, Gonzales, Melissa, Garman, Kristin, Baker, Jason V., Frosch, Anne, Goldsmith, Rachael, Driver, Brian, Frank, Christine, Leviton, Tzivia, Prekker, Matthew, Jibrell, Hodan, Lo, Melanie, Klaphake, Jonathan, Mackedanz, Shari, Ngo, Linh, Garcia-Myers, Kelly, Kunisaki, Ken M., Wendt, Chris, Melzer, Anne, Wetherbee, Erin, Drekonja, Dimitri, Pragman, Alexa, Hamel, Aimee, Thielen, Abbie, Hassler, Miranda, Walquist, Mary, Augenbraun, Michael, George, Jensen, Demeo, Lynette, Mishko, Motria, Thomas, Lorraine, Tatem, Luis, Dehovitz, Jack, Abassi, Mahsa, Leuck, Anne-Marie, Rao, Via, Pullen, Matthew, Luke, Darlette, LaBar, Derek, Christiansen, Theresa, Howard, Diondra, Biswas, Kousick, Harrington, Cristin, Garcia, Amanda, Bremer, Tammy, Burke, Tara, Koker, Brittany, Davis-Karim, Anne, Pittman, David, Vasudeva, Shikha S., Johnstone, Jaylynn R., Agnetti, Kate, Davis, Ruby, Trautner, Barbara, Hines-Munson, Casey, Van, John, Dillon, Laura, Wang, Yiqun, Nagy-Agren, Stephanie, Vasudeva, Shikha, Ochalek, Tracy, Caldwell, Erin, Humerickhouse, Edward, Boone, David, McGraw, William, Looney, David J., Mehta, Sanjay R., Johns, Scott Thompson, St. John, Melissa, Raceles, Jacqueline, Sear, Emily, Funk, Stephen, Cesarini, Rosa, Fang, Michelle, Nicalo, Keith, Drake, Wonder, Jones, Beatrice, Holtman, Teresa, Nguyen, Hien H., Maniar, Archana, Johnson, Eric A., Nguyen, Lam, Tran, Michelle T., Barrett, Thomas W., Johnston, Tera, Huggins, John T., Beiko, Tatsiana Y., Hughes, Heather Y., McManigle, William C., Tanner, Nichole T., Washburn, Ronald G., Ardelt, Magdalena, Tuohy, Patricia A., Mixson, Jennifer L., Hinton, Charles G., Thornley, Nicola, Allen, Heather, Elam, Shannon, Boatman, Barry, Baber, Brittany J., Ryant, Rudell, Roller, Brentin, Nguyen, Chinh, Mikail, Amani Morgan, Research, Marivic Hansen, Lichtenberger, Paola, Baracco, Gio, Ramos, Carol, Bjork, Lauren, Sueiro, Melyssa, Tien, Phyllis, Freasier, Heather, Buck, Theresa, Nekach, Hafida, Holodniy, Mark, Chary, Aarthi, Lu, Kan, Peters, Theresa, Lopez, Jessica, Tan, Susanna Yu, Lee, Robert H., Asghar, Aliya, Karyn Isip, Tasadduq Karim, Le, Katherine, Nguyen, Thao, Wong, Shinn, Raben, Dorthe, Murray, Daniel D., Jensen, Tomas O., Peters, Lars, Aagaard, Bitten, Nielsen, Charlotte B., Krapp, Katharina, Nykjær, Bente Rosdahl, Olsson, Christina, Kanne, Katja Lisa, Grevsen, Anne Louise, Joensen, Zillah Maria, Bruun, Tina, Bojesen, Ane, Woldbye, Frederik, Normand, Nick E., Esman, Frederik V.L., Benfield, Thomas, Clausen, Clara Lundetoft, Hovmand, Nichlas, Israelsen, Simone Bastrup, Iversen, Katrine, Leding, Caecilie, Pedersen, Karen Brorup, Thorlacius-Ussing, Louise, Tinggaard, Michaela, Tingsgard, Sandra, Krohn-Dehli, Louise, Pedersen, Dorthe, Villadsen, Signe, Staehr Jensen, Jens-Ulrik, Overgaard, Rikke, Rastoder, Ema, Heerfordt, Christian, Hedsund, Caroline, Ronn, Christian Phillip, Kamstrup, Peter Thobias, Hogsberg, Dorthe Sandbaek, Bergsoe, Christina, Søborg, Christian, Hissabu, Nuria M.S., Arp, Bodil C., Ostergaard, Lars, Staerke, Nina Breinholt, Yehdego, Yordanos, Sondergaard, Ane, Johansen, Isik S., Pedersen, Andreas Arnholdt, Knudtzen, Fredrikke C., Larsen, Lykke, Hertz, Mathias A., Fabricius, Thilde, Holden, Inge K., Lindvig, Susan O., Helleberg, Marie, Gerstoft, Jan, Kirk, Ole, Jensen, Tomas Ostergaard, Madsen, Birgitte Lindegaard, Pedersen, Thomas Ingemann, Harboe, Zitta Barrella, Roge, Birgit Thorup, Hansen, Thomas Michael, Glesner, Matilde Kanstrup, Lofberg, Sandra Valborg, Nielsen, Ariella Denize, Leicht von Huth, Sebastian, Nielsen, Henrik, Thisted, Rikke Krog, Petersen, Kristine Toft, Juhl, Maria Ruwald, Podlekareva, Daria, Johnsen, Stine, Andreassen, Helle Frost, Pedersen, Lars, Clara Ellinor Lindnér, Cecilia Ebba, Wiese, Lothar, Knudsen, Lene Surland, Skrøder Nytofte, Nikolaj Julian, Havmøller, Signe Ravn, Expósito, Maria, Badillo, José, Martínez, Ana, Abad, Elena, Chamorro, Ana, Figuerola, Ariadna, Mateu, Lourdes, España, Sergio, Lucero, Maria Constanza, Santos, José Ramón, Lladós, Gemma, Lopez, Cristina, Carabias, Lydia, Molina-Morant, Daniel, Loste, Cora, Bracke, Carmen, Siles, Adrian, Fernández-Cruz, Eduardo, Di Natale, Marisa, Padure, Sergiu, Gomez, Jimena, Ausin, Cristina, Cervilla, Eva, Balastegui, Héctor, Sainz, Carmen Rodríguez, Lopez, Paco, Carbone, Javier, Escobar, Mariam, Balerdi, Leire, Legarda, Almudena, Roldan, Montserrat, Letona, Laura, Muñoz, José, Camprubí, Daniel, Arribas, Jose R., Sánchez, Rocio Montejano, Díaz-Pollán, Beatriz, Stewart, Stefan Mark, Garcia, Irene, Borobia, Alberto, Mora-Rillo, Marta, Estrada, Vicente, Cabello, Noemi, Nuñez-Orantos, M.J., Sagastagoitia, I., Homen, J.R., Orviz, E., Montalvá, Adrián Sánchez, Espinosa-Pereiro, Juan, Bosch-Nicolau, Pau, Salvador, Fernando, Burgos, Joaquin, Morales-Rull, Jose Luis, Moreno Pena, Anna Maria, Acosta, Cristina, Solé-Felip, Cristina, Horcajada, Juan P., Sendra, Elena, Castañeda, Silvia, López-Montesinos, Inmaculada, Gómez-Junyent, Joan, Gonzáles, Carlota Gudiol, Cuervo, Guilermo, Pujol, Miquel, Carratalà, Jordi, Videla, Sebastià, Günthard, Huldrych, Braun, Dominique L., West, Emily, M’Rabeth-Bensalah, Khadija, Eichinger, Mareile L., Grüttner-Durmaz, Manuela, Grube, Christina, Zink, Veronika, pharmacist, Goes pharmacist, Josefine, Fätkenheuer, Gerd, Malin, Jakob J., Tsertsvadze, Tengiz, Abutidze, Akaki, Chkhartishvili, Nikoloz, Metchurtchlishvili, Revaz, Endeladze, Marina, Paciorek, Marcin, Bursa, Dominik, Krogulec, Dominika, Pulik, Piotr, Ignatowska, Anna, Horban, Andrzej, Bakowska, Elzbieta, Kowaska, Justyna, Bednarska, Agnieszka, Jurek, Natalia, Skrzat-Klapaczynska, Agata, Bienkowski, Carlo, Hackiewicz, Malgorzata, Makowiecki, Michal, Platowski, Antoni, Fishchuk, Roman, Kobrynska, Olena, Levandovska, Khrystyna, Kirieieva, Ivanna, Kuziuk, Mykhailo, Naucler, Pontus, Perlhamre, Emma, Mazouch, Lotta, Kelleher, Anthony, Polizzotto, Mark, Carey, Catherine, Chang, Christina C., Hough, Sally, Virachit, Sophie, Davidson, Sarah, Bice, Daniel J., Ognenovska, Katherine, Cabrera, Gesalit, Flynn, Ruth, Young, Barnaby E., Chia, Po Ying, Lee, Tau Hong, Lin, Ray J., Lye, David C., Ong, Sean W.X., Puah, Ser Hon, Yeo, Tsin Wen, Diong, Shiau Hui, Ongko, Juwinda, Yeo, He Ping, Eriobu, Nnakelu, Kwaghe, Vivian, Zaiyad, Habib, Idoko, Godwin, Uche, Blessing, Selvamuthu, Poongulali, Kumarasamy, Nagalingeswaran, Beulah, Faith Ester, Govindarajan, Narayan, Mariyappan, Kowsalya, Losso, Marcelo H., Abela, Cecilia, Moretto, Renzo, Belloc, Carlos G., Ludueña, Jael, Amar, Josefina, Toibaro, Javier, Macias, Laura Moreno, Fernandez, Lucia, Frare, Pablo S., Chaio, Sebastian R., Pachioli, Valeria, Timpano, Stella M., Sanchez, Marisa del Lujan, de Paz Sierra, Mariana, Stanek, Vanina, Belloso, Waldo, Cilenti, Flavia L., Valentini, Ricardo N., Stryjewski, Martin E., Locatelli, Nicolas, Soler Riera, Maria C., Salgado, Clara, Baeck, Ines M., Di Castelnuovo, Valentina, Zarza, Stella M., Hudson, Fleur, Parmar, Mahesh K.B., Goodman, Anna L., Dphil, Badrock, Jonathan, Gregory, Adam, Goodall, Katharine, Harris, Nicola, Wyncoll, James, Bhagani, S., Rodger, A., Luntiel, A., Patterson, C., Morales, J., Witele, E., Preston, A.-M., Nandani, A., Price, D.A., Hanrath, Aiden, Nell, Jeremy, Patel, Bijal, Hays, Carole, Jones, Geraldine, Davidson, Jade, Bawa, T., Mathews, M., Mazzella, A., Bisnauthsing, K., Aguilar-Jimenez, L., Borchini, F., Hammett, S., Touloumi, Giota, Pantazis, Nikos, Gioukari, Vicky, Souliou, Tania, Antoniadou, A., Protopapas, K., Kavatha, D., Grigoropoulou, S., Oikonomopoulo, C., Moschopoulos, C., Koulouris, N.G., Tzimopoulos, K., Koromilias, A., Argyraki, K., Lourida, P., Bakakos, P., Kalomenidis, I., Vlachakos, V., Barmparessou, Z., Balis, E., Zakynthinos, S., Sigala, I., Gianniou, N., Dima, E., Magkouta, S., Synolaki, E., Konstanta, S., Vlachou, M., Stathopoulou, P., Panagopoulos, P., Petrakis, V., Papazoglou, D., Tompaidou, E., Isaakidou, E., Poulakou, G., Rapti, V., Leontis, K., Nitsotolis, T., Athanasiou, K., Syrigos, K., Kyriakoulis, K., Trontzas, I., Arfara-Melanini, M., Kolonis, V., Kityo, Cissy, Mugerwa, Henry, Kiweewa, Francis, Kimuli, Ivan, Lukaakome, Joseph, Nsereko, Christoher, Lubega, Gloria, Kibirige, Moses, Nakahima, William, Wangi, Deus, Aguti, Evelyne, Generous, Lilian, Massa, Rosemary, Nalaki, Margaret, Magala, Felix, Nabaggala, Phiona Kaweesi, Kidega, Robert, Faith, Oryem Daizy, Florence, Apio, Emmanuel, Ocung, Beacham, Mugoonyi Paul, Geoffrey, Amone, Nakiboneka, Dridah, Apiyo, Paska, Kirenga, Bruce, Atukunda, Angella, Muttamba, Winters, Remmy, Kyeyume, Segawa, Ivan, Pheona, Nsubuga, Kigere, David, Mbabazi, Queen Lailah, Boersalino, Ledra, Nyakoolo, Grace, Fred, Aniongo, Alupo, Alice, Ebong, Doryn, Monday, Edson, Nalubwama, Ritah Norah, Kainja, Milton, Ambrose, Munu, Kwehayo, Vanon, Nalubega, Mary Grace, Ongoli, Augustine, Obbo, Stephen, Sebudde, Nicholus, Alaba, Jeniffer, Magombe, Geoffrey, Tino, Harriet, Obonya, Emmanuel, Lutaakome, Joseph, Kitonsa, Jonathan, Onyango, Martin, Naboth, Tukamwesiga, Naluyinda, Hadijah, Nanyunja, Regina, Irene, Muttiibwa, Jane, Biira, Wimfred, Kyobejja, Leonard, Ssemazzi, Deus, Tkiinomuhisha, Babra, Namasaba, Taire, Paul, Nabankema, Evelyn, Ogavu, Joseph, Mugerwa, Oscar, Okoth, Ivan, Mwebaze, Raymond, Mugabi, Timothy, Makhoba, Anthony, Arikiriza, Phiona, Theresa, Nabuuma, Nakayima, Hope, Frank, Kisuule, Ramgi, Patrícia, Pereira, Kássia, Osinusi, Anu, Cao, Huyen, Klekotka, Paul, Price, Karen, Nirula, Ajay, Osei, Suzette, Tipple, Craig, Wills, Angela, Peppercorn, Amanda, Watson, Helen, Gupta, Rajesh, Alexander, Elizabeth, Mogalian, Erik, Lin, Leo, Ding, Xiao, Margolis, David, Yan, Li, Girardet, Jean-Luc, Ma, Ji, Hong, Zhi, Zhu, Quing, Seegobin, Seth, Gibbs, Michael, Latchman, Mickel, Hasior, Katarzyna, Bouquet, Jerome, Wei, Jianxin, Streicher, Katie, Schmelzer, Albert, Brooks, Dennis, Butcher, Jonny, Tonev, Dimitar, Arbetter, Douglas, Damstetter, Philippe, Legenne, Philippe, Stumpp, Michael, Goncalves, Susana, Ramanathan, Krishnan, Chandra, Richa, Baseler, Beth, Teitelbaum, Marc, Schechner, Adam, Holley, H. Preston, Jankelevich, Shirley, Becker, Nancy, Dolney, Suzanne, Hissey, Debbie, Simpson, Shelly, Kim, Mi Ha, Beeler, Joy, Harmon, Liam, Asomah, Mabel, Jato, Yvonne, Stottlemyer, April, Tang, Olivia, Vanderpuye, Sharon, Yeon, Lindsey, Buehn, Molly, Eccard-Koons, Vanessa, Frary, Sadie, MacDonald, Leah, Cash, Jennifer, Hoopengardner, Lisa, Linton, Jessica, Schaffhauser, Marylu, Nelson, Michaela, Spinelli-Nadzam, Mary, Proffitt, Calvin, Lee, Christopher, Engel, Theresa, Fontaine, Laura, Osborne, C.K., Hohn, Matt, Galcik, Michael, Thompson, DeeDee, Kopka, Stacey, Shelley, Denise M., Mendez, Gregg, Brown, Shawn, Albert, Sara, Balde, Abby, Baracz, Michelle, Bielica, Mona, Billouin-Frazier, Shere, Choudary, Jay, Dixon, Mary, Eyler, Carolyn, Frye, Leanne, Gertz, Jensen, Giebeig, Lisa, Gulati, Neelam, Hankinson, Liz, Hogarty, Debi, Huber, Lynda, Krauss, Gary, Lake, Eileen, Manandhar, Meryan, Rudzinski, Erin, Sandrus, Jen, Suders, Connie, Natarajan, Ven, Rupert, Adam W., Baseler, Michael, Lynam, Danielle, Imamichi, Tom, Laverdure, Sylvain, McCormack, Ashley, Paudel, Sharada, Cook, Kyndal, Haupt, Kendra, Khan, Ayub, Hazen, Allison, Badralmaa, Yunden, Smith, Kenneth, Patel, Bhakti, Kubernac, Amanda, Kubernac, Robert, Hoover, Marie L., Solomon, Courtney, Rashid, Marium, Murphy, Joseph, Brown, Craig, DuChateau, Nadine, Ellis, Sadie, Flosi, Adam, Fox, Lisa, Johnson, Les, Nelson, Rich, Stojanovic, Jelena, Treagus, Amy, Wenner, Christine, Williams, Richard, Jensen, Tomas O, Murray, Thomas A, Grandits, Greg A, Jain, Mamta K, Shaw-Saliba, Kathryn, Matthay, Michael A, Baker, Jason V, Dewar, Robin L, Goodman, Anna L, Hatlen, Timothy J, Highbarger, Helene C, Lallemand, Perrine, Leshnower, Bradley G, Looney, David, Moschopoulos, Charalampos D, Murray, Daniel D, Mylonakis, Eleftherios, Rehman, M Tauseef, Rupert, Adam, Stevens, Randy, Turville, Stuart, Wick, Katherine, Lundgren, Jens, and Ko, Emily R

Published
2024
Full Text
View/download PDF

12. Early Outpatient Treatment for Covid-19 with Convalescent Plasma

Author

Sullivan, David J, Gebo, Kelly A, Shoham, Shmuel, Bloch, Evan M, Lau, Bryan, Shenoy, Aarthi G, Mosnaim, Giselle S, Gniadek, Thomas J, Fukuta, Yuriko, Patel, Bela, Heath, Sonya L, Levine, Adam C, Meisenberg, Barry R, Spivak, Emily S, Anjan, Shweta, Huaman, Moises A, Blair, Janis E, Currier, Judith S, Paxton, James H, Gerber, Jonathan M, Petrini, Joann R, Broderick, Patrick B, Rausch, William, Cordisco, Marie-Elena, Hammel, Jean, Greenblatt, Benjamin, Cluzet, Valerie C, Cruser, Daniel, Oei, Kevin, Abinante, Matthew, Hammitt, Laura L, Sutcliffe, Catherine G, Forthal, Donald N, Zand, Martin S, Cachay, Edward R, Raval, Jay S, Kassaye, Seble G, Foster, E Colin, Roth, Michael, Marshall, Christi E, Yarava, Anusha, Lane, Karen, McBee, Nichol A, Gawad, Amy L, Karlen, Nicky, Singh, Atika, Ford, Daniel E, Jabs, Douglas A, Appel, Lawrence J, Shade, David M, Ehrhardt, Stephan, Baksh, Sheriza N, Laeyendecker, Oliver, Pekosz, Andrew, Klein, Sabra L, Casadevall, Arturo, Tobian, Aaron AR, and Hanley, Daniel F

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Clinical Trials and Supportive Activities, Neurodegenerative, Patient Safety, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Ambulatory Care, COVID-19, Disease Progression, Double-Blind Method, Hospitalization, Humans, Immunization, Passive, Treatment Outcome, United States, COVID-19 Serotherapy, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundPolyclonal convalescent plasma may be obtained from donors who have recovered from coronavirus disease 2019 (Covid-19). The efficacy of this plasma in preventing serious complications in outpatients with recent-onset Covid-19 is uncertain.MethodsIn this multicenter, double-blind, randomized, controlled trial, we evaluated the efficacy and safety of Covid-19 convalescent plasma, as compared with control plasma, in symptomatic adults (≥18 years of age) who had tested positive for severe acute respiratory syndrome coronavirus 2, regardless of their risk factors for disease progression or vaccination status. Participants were enrolled within 8 days after symptom onset and received a transfusion within 1 day after randomization. The primary outcome was Covid-19-related hospitalization within 28 days after transfusion.ResultsParticipants were enrolled from June 3, 2020, through October 1, 2021. A total of 1225 participants underwent randomization, and 1181 received a transfusion. In the prespecified modified intention-to-treat analysis that included only participants who received a transfusion, the primary outcome occurred in 17 of 592 participants (2.9%) who received convalescent plasma and 37 of 589 participants (6.3%) who received control plasma (absolute risk reduction, 3.4 percentage points; 95% confidence interval, 1.0 to 5.8; P = 0.005), which corresponded to a relative risk reduction of 54%. Evidence of efficacy in vaccinated participants cannot be inferred from these data because 53 of the 54 participants with Covid-19 who were hospitalized were unvaccinated and 1 participant was partially vaccinated. A total of 16 grade 3 or 4 adverse events (7 in the convalescent-plasma group and 9 in the control-plasma group) occurred in participants who were not hospitalized.ConclusionsIn participants with Covid-19, most of whom were unvaccinated, the administration of convalescent plasma within 9 days after the onset of symptoms reduced the risk of disease progression leading to hospitalization. (Funded by the Department of Defense and others; CSSC-004 ClinicalTrials.gov number, NCT04373460.).

Published
2022

13. How do I implement an outpatient program for the administration of convalescent plasma for COVID‐19?

Author

Bloch, Evan M, Tobian, Aaron AR, Shoham, Shmuel, Hanley, Daniel F, Gniadek, Thomas J, Cachay, Edward R, Meisenberg, Barry R, Kafka, Kimberly, Marshall, Christi, Heath, Sonya L, Shenoy, Aarthi, Paxton, James H, Levine, Adam, Forthal, Donald, Fukuta, Yuriko, Huaman, Moises A, Ziman, Alyssa, Adamski, Jill, Gerber, Jonathan, Cruser, Daniel, Kassaye, Seble G, Mosnaim, Giselle S, Patel, Bela, Metcalf, Ryan A, Anjan, Shweta, Reisler, Ronald B, Yarava, Anusha, Lane, Karen, McBee, Nichol, Gawad, Amy, Raval, Jay S, Zand, Martin, Abinante, Matthew, Broderick, Patrick B, Casadevall, Arturo, Sullivan, David, and Gebo, Kelly A

Subjects
Emerging Infectious Diseases, Prevention, Infectious Diseases, Good Health and Well Being, COVID-19, Humans, Immunization, Passive, Outpatients, Pandemics, SARS-CoV-2, United States, COVID-19 Serotherapy, ambulatory care, antibodies, blood transfusion, COVID-19 serotherapy, monoclonal, plasma, Cardiorespiratory Medicine and Haematology, Clinical Sciences, Immunology, Cardiovascular System & Hematology
Abstract

Convalescent plasma, collected from donors who have recovered from a pathogen of interest, has been used to treat infectious diseases, particularly in times of outbreak, when alternative therapies were unavailable. The COVID-19 pandemic revived interest in the use of convalescent plasma. Large observational studies and clinical trials that were executed during the pandemic provided insight into how to use convalescent plasma, whereby high levels of antibodies against the pathogen of interest and administration early within the time course of the disease are critical for optimal therapeutic effect. Several studies have shown outpatient administration of COVID-19 convalescent plasma (CCP) to be both safe and effective, preventing clinical progression in patients when administered within the first week of COVID-19. The United States Food and Drug Administration expanded its emergency use authorization (EUA) to allow for the administration of CCP in an outpatient setting in December 2021, at least for immunocompromised patients or those on immunosuppressive therapy. Outpatient transfusion of CCP and infusion of monoclonal antibody therapies for a highly transmissible infectious disease introduces nuanced challenges related to infection prevention. Drawing on our experiences with the clinical and research use of CCP, we describe the logistical considerations and workflow spanning procurement of qualified products, infrastructure, staffing, transfusion, and associated management of adverse events. The purpose of this description is to facilitate the efforts of others intent on establishing outpatient transfusion programs for CCP and other antibody-based therapies.

Published
2022

17. Real-time Prediction for Mechanical Ventilation in COVID-19 Patients using A Multi-task Gaussian Process Multi-objective Self-attention Network

Author

Zhang, Kai, Karanth, Siddharth, Patel, Bela, Murphy, Robert, and Jiang, Xiaoqian

Subjects
Computer Science - Machine Learning, Statistics - Applications
Abstract

We propose a robust in-time predictor for in-hospital COVID-19 patient's probability of requiring mechanical ventilation. A challenge in the risk prediction for COVID-19 patients lies in the great variability and irregular sampling of patient's vitals and labs observed in the clinical setting. Existing methods have strong limitations in handling time-dependent features' complex dynamics, either oversimplifying temporal data with summary statistics that lose information or over-engineering features that lead to less robust outcomes. We propose a novel in-time risk trajectory predictive model to handle the irregular sampling rate in the data, which follows the dynamics of risk of performing mechanical ventilation for individual patients. The model incorporates the Multi-task Gaussian Process using observed values to learn the posterior joint multi-variant conditional probability and infer the missing values on a unified time grid. The temporal imputed data is fed into a multi-objective self-attention network for the prediction task. A novel positional encoding layer is proposed and added to the network for producing in-time predictions. The positional layer outputs a risk score at each user-defined time point during the entire hospital stay of an inpatient. We frame the prediction task into a multi-objective learning framework, and the risk scores at all time points are optimized altogether, which adds robustness and consistency to the risk score trajectory prediction. Our experimental evaluation on a large database with nationwide in-hospital patients with COVID-19 also demonstrates that it improved the state-of-the-art performance in terms of AUC (Area Under the receiver operating characteristic Curve) and AUPRC (Area Under the Precision-Recall Curve) performance metrics, especially at early times after hospital admission., Comment: In review

Published
2021

19. Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study

Author

Zhu, Xianming, Gebo, Kelly A, Abraham, Alison G, Habtehyimer, Feben, Patel, Eshan U, Laeyendecker, Oliver, Gniadek, Thomas J, Fernandez, Reinaldo E, Baker, Owen R, Ram, Malathi, Cachay, Edward R, Currier, Judith S, Fukuta, Yuriko, Gerber, Jonathan M, Heath, Sonya L, Meisenberg, Barry, Huaman, Moises A, Levine, Adam C, Shenoy, Aarthi, Anjan, Shweta, Blair, Janis E, Cruser, Daniel, Forthal, Donald N, Hammitt, Laura L, Kassaye, Seble, Mosnaim, Giselle S, Patel, Bela, Paxton, James H, Raval, Jay S, Sutcliffe, Catherine G, Abinante, Matthew, Broderick, Patrick, Cluzet, Valerie, Cordisco, Marie Elena, Greenblatt, Benjamin, Petrini, Joann, Rausch, William, Shade, David, Lane, Karen, Gawad, Amy L, Klein, Sabra L, Pekosz, Andrew, Shoham, Shmuel, Casadevall, Arturo, Bloch, Evan M, Hanley, Daniel, Sullivan, David J, and Tobian, Aaron A R

Published
2023
Full Text
View/download PDF

20. Diagnostic utility of whole genome sequencing in adults with B-other acute lymphoblastic leukemia

Author

Leongamornlert, Daniel, Gutiérrez-Abril, Jesús, Lee, SooWah, Barretta, Emilio, Creasey, Thomas, Gundem, Gunes, Levine, Max F., Arango-Ossa, Juan E., Liosis, Konstantinos, Medina-Martinez, Juan S., Zuborne Alapi, Krisztina, Kirkwood, Amy A., Clifton-Hadley, Laura, Patrick, Pip, Jones, David, O’Neill, Laura, Butler, Adam P., Harrison, Christine J., Campbell, Peter, Patel, Bela, Moorman, Anthony V., Fielding, Adele K., and Papaemmanuil, Elli

Published
2023
Full Text
View/download PDF

22. Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia

Author

Patel, Bela, primary, Kirkwood, Amy A., additional, Rowntree, Clare J., additional, Alapi, Krisztina Z., additional, Barretta, Emilio, additional, Clifton‐Hadley, Laura, additional, Creasey, Tom, additional, Lee, SooWah, additional, Marks, David I., additional, Moorman, Anthony V., additional, Morley, Nicholas, additional, Patrick, Pip, additional, Rana, Zaynab, additional, Rijneveld, Anita, additional, Snowden, John A., additional, and Fielding, Adele K., additional

Published
2024
Full Text
View/download PDF

23. Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern

Author

Li, Maggie, Beck, Evan J., Laeyendecker, Oliver, Eby, Yolanda, Tobian, Aaron A.R., Caturegli, Patrizio, Wouters, Camille, Chiklis, Gregory R., Block, William, McKie, Robert O., Joyner, Michael J., Wiltshire, Timothy D., Dietz, Allan B., Gniadek, Thomas J., Shapiro, Arell J., Yarava, Anusha, Lane, Karen, Hanley, Daniel F., Bloch, Evan M., Shoham, Shmuel, Cachay, Edward R., Meisenberg, Barry R., Huaman, Moises A., Fukuta, Yuriko, Patel, Bela, Heath, Sonya L., Levine, Adam C., Paxton, James H., Anjan, Shweta, Gerber, Jonathan M., Gebo, Kelly A., Casadevall, Arturo, Pekosz, Andrew, and Sullivan, David J.

Published
2022
Full Text
View/download PDF

26. Prognostic impact of chromosomal abnormalities and copy number alterations in adult B-cell precursor acute lymphoblastic leukaemia: a UKALL14 study

Author

Moorman, Anthony V., Barretta, Emilio, Butler, Ellie R., Ward, Eleanor J., Twentyman, Katie, Kirkwood, Amy A., Enshaei, Amir, Schwab, Claire, Creasey, Tom, Leongamornlert, Daniel, Papaemmanuil, Elli, Patrick, Pip, Clifton-Hadley, Laura, Patel, Bela, Menne, Tobias, McMillan, Andrew K., Harrison, Christine J., Rowntree, Clare J., Marks, David I., and Fielding, Adele K.

Published
2022
Full Text
View/download PDF

27. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial

Author

Marks, David I, Kirkwood, Amy A, Rowntree, Clare J, Aguiar, Melanie, Bailey, Katharine E, Beaton, Brendan, Cahalin, Paul, Castleton, Anna Z, Clifton-Hadley, Laura, Copland, Mhairi, Goldstone, Anthony H, Kelly, Richard, Lawrie, Emma, Lee, SooWah, McMillan, Andrew K, McMullin, Mary Frances, Menne, Tobias F, Mitchell, Rachel J, Moorman, Anthony V, Patel, Bela, Patrick, Pip, Smith, Paul, Taussig, David, Yallop, Deborah, Alapi, Krisztina Zuborne, and Fielding, Adele K

Published
2022
Full Text
View/download PDF

28. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial

Author

Marks, David I, Clifton-Hadley, Laura, Copland, Mhairi, Hussain, Jiaull, Menne, Tobias F, McMillan, Andrew, Moorman, Anthony V, Morley, Nicholas, Okasha, Dina, Patel, Bela, Patrick, Pip, Potter, Michael N, Rowntree, Clare J, Kirkwood, Amy A, and Fielding, Adele K

Published
2022
Full Text
View/download PDF

31. IKZF1 alterations are not associated with outcome in 498 adults with B-precursor ALL enrolled in the UKALL14 trial

Author

Mitchell, Rachel J., Kirkwood, Amy A., Barretta, Emilio, Clifton-Hadley, Laura, Lawrie, Emma, Lee, SooWah, Leongamornlert, Daniel, Marks, David I., McMillan, Andrew K., Menne, Tobias F., Papaemmanuil, Elli, Patel, Bela, Patrick, Pip, Rowntree, Clare J., Zareian, Nahid, Alapi, Krisztina Zuborne, Moorman, Anthony V., and Fielding, Adele K.

Published
2021
Full Text
View/download PDF

33. Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation

Author

Dembitz, Vilma, Lawson, Hannah, Burt, Richard, Natani, Sirisha, Philippe, Céline, James, Sophie C., Atkinson, Samantha, Durko, Jozef, Wang, Lydia M., Campos, Joana, Magee, Aoife M. S., Woodley, Keith, Austin, Michael J., Rio-Machin, Ana, Casado, Pedro, Bewicke-Copley, Findlay, Rodriguez Blanco, Giovanny, Pereira-Martins, Diego, Oudejans, Lieve, Boet, Emeline, von Kriegsheim, Alex, Schwaller, Juerg, Finch, Andrew J., Patel, Bela, Sarry, Jean-Emmanuel, Tamburini, Jerome, Schuringa, Jan Jacob, Hazlehurst, Lori, Copland III, John A., Yuneva, Mariia, Peck, Barrie, Cutillas, Pedro, Fitzgibbon, Jude, Rouault-Pierre, Kevin, Kranc, Kamil, and Gallipoli, Paolo

Abstract

Identification of specific and therapeutically actionable vulnerabilities, ideally present across multiple mutational backgrounds, is needed to improve acute myeloid leukemia (AML) patients’ outcomes. We identify stearoyl-CoA desaturase (SCD), the key enzyme in fatty acid (FA) desaturation, as prognostic of patients' outcomes and, using the clinical-grade inhibitor SSI-4, show that SCD inhibition (SCDi) is a therapeutic vulnerability across multiple AML models in vitro and in vivo. Multiomic analysis demonstrates that SCDi causes lipotoxicity, which induces AML cell death viapleiotropic effects. Sensitivity to SCDi correlates with AML dependency on FA desaturation regardless of mutational profile and is modulated by FA biosynthesis activity. Finally, we show that lipotoxicity increases chemotherapy-induced DNA damage and standard chemotherapy further sensitizes AML cells to SCDi. Our work supports developing FA desaturase inhibitors in AML while stressing the importance of identifying predictive biomarkers of response and biologically validated combination therapies to realize their full therapeutic potential.

Published
2024
Full Text
View/download PDF

40. 840. Risk-Based Screening on Admission Cultures (SOAC) vs. Unit-Wide Reactionary Surveillance Cultures (UWRC) for Candida auris: A Pilot QI Study in a Tertiary Care Center ICU

Author

Strong, Nora, primary, Patel, Bela, additional, Daniels, LaRhonda, additional, Ausborn, Valerie, additional, Mitchell, Elizabeth, additional, Denman, Chris, additional, Von Wenckstern, Toni, additional, Ellsworth, Misti G, additional, Ostrosky-Zeichner, Luis, additional, and Wanger, Audrey, additional

Published
2023
Full Text
View/download PDF

41. 401. Risk of Post-COVID Conditions Correlates with IL-6 Plasma Levels and Is Reduced by Early Antibody Therapy

Author

Fukuta, Yuriko, primary, Gebo, Kelly, additional, Heath, Sonya L, additional, Zhu, Xianming, additional, Baksh, Sheriza, additional, Abraham, Alison G, additional, Habtehyimer, Feben, additional, Shade, David, additional, Ruff, Jessica E, additional, Ram, Malathi, additional, Laeyendecker, Oliver, additional, Fernandez, Reinaldo, additional, Patel, Eshan U, additional, Baker, Owen R, additional, Shoham, Shmuel, additional, Cachay, Edward R, additional, Currier, Judith S, additional, Gerber, Jonathan, additional, Meisenberg, Barry, additional, Hammitt, Laura, additional, Forthal, Donald, additional, Huaman, Moises A, additional, Levine, Adam C, additional, Mosnaim, Giselle, additional, Patel, Bela, additional, Paxton, James, additional, Raval, Jay S, additional, Sutcliffe, Catherine, additional, Anjan, Shweta, additional, Gniadek, Thomas, additional, Kassaye, Seble, additional, Blair, Janis E, additional, Lane, Karen, additional, McBee, Nichol, additional, Gawad, Amy, additional, Das, Piyali, additional, Klein, Sabra L, additional, Pekosz, Andrew, additional, Bloch, Evan, additional, Hanley, Daniel, additional, Casadevall, Arturo, additional, Tobian, Aaron, additional, and Sullivan, David, additional

Published
2023
Full Text
View/download PDF

42. COVID-19 convalescent plasma therapy decreases inflammatory cytokines: a randomized controlled trial

Author

Habtehyimer, Feben, primary, Zhu, Xianming, additional, Redd, Andrew D., additional, Gebo, Kelly A., additional, Abraham, Alison G., additional, Patel, Eshan U., additional, Laeyendecker, Oliver, additional, Gniadek, Thomas J., additional, Fernandez, Reinaldo E., additional, Baker, Owen R., additional, Ram, Malathi, additional, Cachay, Edward R., additional, Currier, Judith S., additional, Fukuta, Yuriko, additional, Gerber, Jonathan M., additional, Heath, Sonya L., additional, Meisenberg, Barry, additional, Huaman, Moises A., additional, Levine, Adam C., additional, Shenoy, Aarthi, additional, Anjan, Shweta, additional, Blair, Janis E., additional, Cruser, Daniel, additional, Forthal, Donald N., additional, Hammitt, Laura L., additional, Kassaye, Seble, additional, Mosnaim, Giselle S., additional, Patel, Bela, additional, Paxton, James H., additional, Raval, Jay S., additional, Sutcliffe, Catherine G., additional, Abinante, Matthew, additional, Oei, Kevin S., additional, Cluzet, Valerie, additional, Cordisco, Marie Elena, additional, Greenblatt, Benjamin, additional, Rausch, William, additional, Shade, David, additional, Gawad, Amy L., additional, Klein, Sabra L., additional, Pekosz, Andrew, additional, Shoham, Shmuel, additional, Casadevall, Arturo, additional, Bloch, Evan M., additional, Hanley, Daniel, additional, Tobian, Aaron A. R., additional, and Sullivan, David J., additional

Published
2023
Full Text
View/download PDF

43. COVID-19 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization

Author

Levine, Adam C, Fukuta, Yuriko, Huaman, Moises A, Ou, Jiangda, Meisenberg, Barry R, Patel, Bela, Paxton, James H, Hanley, Daniel F, Rijnders, Bart Ja, Gharbharan, Arvind, Rokx, Casper, Zwaginga, Jaap Jan, Alemany, Andrea, Mitjà, Oriol, Ouchi, Dan, Millat-Martinez, Pere, Durkalski-Mauldin, Valerie, Korley, Frederick K, Dumont, Larry J, Callaway, Clifton W, Libster, Romina, Marc, Gonzalo Perez, Wappner, Diego, Esteban, Ignacio, Polack, Fernando, Sullivan, David J, Internal Medicine, Surgery, and Medical Microbiology & Infectious Diseases

Subjects
Microbiology (medical), Infectious Diseases
Abstract

Background Outpatient monoclonal antibodies are no longer effective and antiviral treatments for coronavirus disease 2019 (COVID-19) disease remain largely unavailable in many countries worldwide. Although treatment with COVID-19 convalescent plasma (CCP) is promising, clinical trials among outpatients have shown mixed results. Methods We conducted an individual participant data meta-analysis from outpatient trials to assess the overall risk reduction for all-cause hospitalizations by day 28 in transfused participants. Relevant trials were identified by searching Medline, Embase, medRxiv, World Health Organization COVID-19 Research Database, Cochrane Library, and Web of Science from January 2020 to September 2022. Results Five included studies from 4 countries enrolled and transfused 2620 adult patients. Comorbidities were present in 1795 (69%). The virus neutralizing antibody dilutional titer levels ranged from 8 to 14 580 in diverse assays. One hundred sixty of 1315 (12.2%) control patients were hospitalized, versus 111 of 1305 (8.5%) CCP-treated patients, yielding a 3.7% (95% confidence interval [CI], 1.3%–6.0%; P = .001) absolute risk reduction and 30.1% relative risk reduction for all-cause hospitalization. The hospitalization reduction was greatest in those with both early transfusion and high titer with a 7.6% absolute risk reduction (95% CI, 4.0%–11.1%; P = .0001) accompanied by at 51.4% relative risk reduction. No significant reduction in hospitalization was seen with treatment >5 days after symptom onset or in those receiving CCP with antibody titers below the median titer. Conclusions Among outpatients with COVID-19, treatment with CCP reduced the rate of all-cause hospitalization and may be most effective when given within 5 days of symptom onset and when antibody titer is higher.

Published
2023

44. A Multicenter Retrospective Cohort Study to Characterize Patients Hospitalized With Multisystem Inflammatory Syndrome in Adults and Coronavirus Disease 2019 in the United States, 2020–2021

Author

Melgar, Michael, primary, Abrams, Joseph Y, additional, Godfred-Cato, Shana, additional, Shah, Ami B, additional, Garg, Amit, additional, Strunk, Andrew, additional, Narasimhan, Mangala, additional, Koptyev, Jonathan, additional, Norden, Alexandra, additional, Musheyev, David, additional, Rashid, Fahmida, additional, Tannenbaum, Rachel, additional, Estrada-Y-Martin, Rosa M, additional, Patel, Bela, additional, Karanth, Siddharth, additional, Achenbach, Chad J, additional, Hall, Gavin T, additional, Hockney, Sara M, additional, Caputo, Matthew, additional, Abbo, Lilian M, additional, Beauchamps, Laura, additional, Morris, Stephen, additional, Cifuentes, Renzo O, additional, de St Maurice, Annabelle, additional, Bell, Douglas S, additional, Prabaker, Kavitha K, additional, Sanz Vidorreta, Fernando J, additional, Bryant, Evan, additional, Cohen, David K, additional, Mohan, Rohith, additional, Libby, Christopher P, additional, SooHoo, Spencer, additional, Domingo, Tristel J, additional, Campbell, Angela P, additional, and Belay, Ermias D, additional

Published
2023
Full Text
View/download PDF

45. Efficacy and safety of MAS825 (anti-IL-1β/IL-18) in COVID-19 patients with pneumonia and impaired respiratory function

Author

Hakim, Alex D, primary, Awili, Mustafa, additional, O’Neal, Hollis R, additional, Siddiqi, Omar, additional, Jaffrani, Naseem, additional, Lee, Richard, additional, Overcash, Jeffrey S, additional, Chauffe, Ann, additional, Hammond, Terese C, additional, Patel, Bela, additional, Waters, Michael, additional, Criner, Gerard J, additional, Pachori, Alok, additional, Junge, Guido, additional, Levitch, Rafael, additional, Watts, Jen, additional, Koo, Philip, additional, Sengupta, Tirtha, additional, Yu, Lili, additional, Kiffe, Michael, additional, Pinck, Anne, additional, Stein, Richard R, additional, Bendrick-Peart, Jamie, additional, Jenkins, Janet, additional, Rowlands, Marianna, additional, Waldron-Lynch, Frank, additional, and Matthews, Jesse, additional

Published
2023
Full Text
View/download PDF

47. The Role of Palliative Care Consultation in Withdrawal of Life-Sustaining Treatment among ICU Patients Receiving Veno-Venous Extracorporeal Membrane Oxygenation (VV-ECMO): A Retrospective Case-Control Study.

Author

Patarroyo - Aponte, Gabriel, Shoar, Saeed, Ashley, Deptmer M., Noorbaksh, Ali, Patel, Dev, Young, Alisha Y., Akkanti, Bindu H., Warner, Mark T., Patarroyo - Aponte, Maria M., Kar, Biswajit, Gregoric, Igor D., Ha, Caroline, and Patel, Bela

Abstract

Background: Extracorporeal membrane oxygenation (ECMO) has extended the survivability of critically ill patients beyond their unsupported prognosis and has widened the timeframe for making an informed decision about the goal of care. However, an extended time window for survival does not necessarily translate into a better outcome and the sustaining treatment is ultimately withdrawn in many patients. Emerging evidence has implicated the determining role of palliative care consult (PCC) in direction of the care that critically ill patients receive. Objective: To evaluate the impact of PCC in withdrawal of life-sustaining treatment (WOLST) among critically ill patients, who were placed on venovenous ECMO (VV-ECMO) at the intensive care unit (ICU) of a tertiary care hospital. Methods: In a retrospective observational study, electronic medical records of 750 patients admitted to the ICU of our hospital between January 1, 2015, and October 31, 2021, were reviewed. Data was collected for patients on VV-ECMO, for whom WOLST was withdrawn during the ICU stay. Clinical characteristics and the underlying reasons for WOLST were compared between those who received PCC (PCC group) and those who did not (non-PCC group). Results: A total of 95 patients were included in our analysis, 63 in the PCC group and 32 in the non-PCC group. The average age of the study population was 48.8 ± 12.6 years, and 64.2% were male. There was no statistically significant difference between the two groups in terms of demographics or clinical characteristics at the time of ICU admission. The average duration of ICU stay and VV-ECMO were 14.1 ± 19.9 days and 9.4 ± 16.6 days, respectively. The number of PCC visits was correlated with the length of ICU stay. The average duration of ICU stay (40.3 ± 33.2 days vs 27.8 ± 19.3 days, P =.05) and ECMO treatment (31.9 ± 27 days vs 18.6 ± 16.1 days, P =.01) were significantly longer in patients receiving PCC than those not receiving PCC. However, the frequency of life sustaining measures or the underlying reasons for WOLST did not significantly differ between the two groups (P >.05). Conclusion: Among ICU patients requiring ECMO support, longer duration of ICU stay and treatment with a higher number of life-sustaining measures seemed to be correlated with the number of PCC visits. The underlying reasons for WOLST seem not to be affected by PCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

48. Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial

Author

Park, Han-Sol, primary, Yin, Anna, additional, Barranta, Caelan, additional, Lee, John S., additional, Caputo, Christopher A., additional, Sachithanandham, Jaiprasath, additional, Li, Maggie, additional, Yoon, Steve, additional, Sitaras, Ioannis, additional, Jedlicka, Anne, additional, Eby, Yolanda, additional, Ram, Malathi, additional, Fernandez, Reinaldo E., additional, Baker, Owen R., additional, Shenoy, Aarthi G., additional, Mosnaim, Giselle S., additional, Fukuta, Yuriko, additional, Patel, Bela, additional, Heath, Sonya L., additional, Levine, Adam C., additional, Meisenberg, Barry R., additional, Spivak, Emily S., additional, Anjan, Shweta, additional, Huaman, Moises A., additional, Blair, Janis E., additional, Currier, Judith S., additional, Paxton, James H., additional, Gerber, Jonathan M., additional, Petrini, Joann R., additional, Broderick, Patrick B., additional, Rausch, William, additional, Cordisco, Marie Elena, additional, Hammel, Jean, additional, Greenblatt, Benjamin, additional, Cluzet, Valerie C., additional, Cruser, Daniel, additional, Oei, Kevin, additional, Abinante, Matthew, additional, Hammitt, Laura L., additional, Sutcliffe, Catherine G., additional, Forthal, Donald N., additional, Zand, Martin S., additional, Cachay, Edward R., additional, Raval, Jay S., additional, Kassaye, Seble G., additional, Marshall, Christi E., additional, Yarava, Anusha, additional, Lane, Karen, additional, McBee, Nichol A., additional, Gawad, Amy L., additional, Karlen, Nicky, additional, Singh, Atika, additional, Ford, Daniel E., additional, Jabs, Douglas A., additional, Appel, Lawrence J., additional, Shade, David M., additional, Lau, Bryan, additional, Ehrhardt, Stephan, additional, Baksh, Sheriza N., additional, Shapiro, Janna R., additional, Ou, Jiangda, additional, Na, Yu Bin, additional, Knoll, Maria D., additional, Ornelas-Gatdula, Elysse, additional, Arroyo-Curras, Netzahualcoyotl, additional, Gniadek, Thomas J., additional, Caturegli, Patrizio, additional, Wu, Jinke, additional, Ndahiro, Nelson, additional, Betenbaugh, Michael J., additional, Ziman, Alyssa, additional, Hanley, Daniel F., additional, Casadevall, Arturo, additional, Shoham, Shmuel, additional, Bloch, Evan M., additional, Gebo, Kelly A., additional, Tobian, Aaron A.R., additional, Laeyendecker, Oliver, additional, Pekosz, Andrew, additional, Klein, Sabra L., additional, and Sullivan, David J., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results